Evidence-Based Complementary and Alternative Medicine the Tianjin Tasly Pharmaceutical Corporation. Dr. Z.-X. Guo and Ms. R. Luo are employees of the Tasly Pharmaceutical Corporation. References [1] R. Kacimi, J. Karlina, F. Koudssi, and C. Long, “Expression and regulation of adhesion molecules in cardiac cells by cytokines response to acute hypoxia,” Circulation Research, vol. 82, pp. 576–586, 1998. [2] S. Blankenberg, S. Barbaux, and L. Tiret, “Adhesion molecules and atherosclerosis,” Atherosclerosis, vol. 170, no. 2, pp. 191– 203, 2003. [3] P. M. Ridker, C. H. Hennekens, J. E. Buring, and N. Rifai, “C-reactive protein and other markers of inﬂammation in the prediction of cardiovascular disease in women,” The New England Journal of Medicine, vol. 342, pp. 836–843, 2000. [4] S.-J. Hwang, C. M. Ballantyne, A. R. Sharrett et al., “Circulat- ing adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease,” Circulation, vol. 96, no. 12, pp. 4219–4225, 1997. [5] P. M. Ridker, J. E. Buring, and N. Rifai, “Soluble P-selectin and the risk of future cardiovascular events,” Circulation, vol. 103, no. 4, pp. 491–495, 2001. [6] A. Nasuno, T. Matsubara, T. Hori et al., “Levels of soluble E- selectin and ICAM-1 in the coronary circulation of patients with stable coronary artery disease: association with the severity of coronary atherosclerosis,” Japanese Heart Journal, vol. 43, no. 2, pp. 93–101, 2002. [7] G. J. Blake and P. M. Ridker, “Inﬂammatory bio-markers and cardiovascular risk prediction,” Journal of Internal Medicine, vol. 252, no. 4, pp. 283–294, 2002. [8] J. C. Tardif, J. Gre´goire, M. A. Lavoie, and P. L. L’Allier, “Vascular protectants for the treatment of atherosclerosis,” Expert Review of Cardiovascular Therapy, vol. 1, no. 3, pp. 385– 392, 2003. [9] S. H. Merchant, D. M. Gurule, and R. S. Larson, “Amelioration of ischemia-reperfusion injury with cyclic peptide blockade of ICAM-1,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 284, no. 4, pp. H1260–H1268, 2003. [10] Pharmacopoeia Commission of P.R. China, Pharmacopoeia of the People’s Republic of China, Guangdong Science and Technology Press, Guangzhou,China, 1992. [11] F. Wang, Y. Y. Liu, L. Y. Liu, J. Guo, K. Sun, C. S. Wang et al., “Inhibition eﬀect of Dantonic pills on venous thrombosis induced in rat mesentery by photochemical reaction,” Clinical Hemorheology and Microcirculation, vol. 34, pp. 131–138, 2006. [12] J. Guo, L. Zhang, Y. Jiang, Z. Zeng, D. Sun, W. Ka et al., “Eﬀects of compound Dan-shen root dropping pill on hemorheology in high-fat diet induced hyperlipidemia in dogs,” Clinical Hemorheology and Microcirculation, vol. 32, pp. 19–30, 2005. [13] S. Ling, A. Dai, Z. Guo, X. Yan, and P. A. Komesaroﬀ, “Eﬀects of a Chinese herbal preparation on vascular cells in culture: mechanisms of cardiovascular protection,” Clinical and Experimental Pharmacology and Physiology, vol. 32, no. 7, pp. 571–578, 2005. [14] S. Ling, L. Nheu, A. Dai, Z. X. Guo, and P. A. Komesaroﬀ, “Eﬀects of four medicinal herbs on human vascular endothe- lial cells in culture,” International Journal of Cardiology, vol. 128, no. 3, pp. 350–358, 2008. 5 [15] S. Ling, A. Dai, Z. X. Guo, and P. A. Komesaroﬀ, “A preparation of herbal medicine salvia miltiorrhiza reduces expression of intracellular adhesion molecule-1 and develop- ment of atherosclerosis in ApoE-deﬁcient mice,” Journal of Cardiovascular Pharmacology, vol. 51, pp. 38–44, 2008. [16] Drug Policy Bureau of the Ministry of Health, New Drug (Chi- neseMedicine) Pre-Clinical Research Guidelines, Ministryof Health of China, Beijing, China, 1993. [17] J. A. H. Baecke, J. Burema, and J. E. R. Frijters, “A short questionnaire for the measurement of habitual physical activ- ity in epidemiological studies,” American Journal of Clinical Nutrition, vol. 36, no. 5, pp. 936–942, 1982. [18] K. M. Wood, M. D. Cadogan, A. L. Ramshaw, and D. V. Parums, “The distribution of adhesion molecules in human atherosclerosis,” Histopathology, vol. 22, pp. 437–444, 1993. [19] K. Zibara, E. Chignier, C. Covacho, R. Poston, G. Canard, P. Hardy et al., “Modulation of expression of endothelial intercellular adhesion molecule-1, platelet-endothelial cell adhesion molecule-1, and vascular cell adhesion molecule-1 in aortic arch lesions of apolipoprotein E-deﬁcient compared with wild-type mice,” Arteriosclerosis, Thrombosis, and Vascu- lar Biology, vol. 20, pp. 2288–2296, 2000. [20] G. K. Hansson, “Immune mechanisms in atherosclerosis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 12, pp. 1876–1890, 2001. [21] M. P. Bevilacqua, J. S. Pober, D. L. Mendrick, R. S. Cotran, and M. A. Gimbrone Jr., “Identiﬁcation of an inducible endothelial-leukocyte adhesion molecule,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 24, pp. 9238–9242, 1987. [22] K. Peter, P. Nowroth, C. Contadt, T. Nordt, T. Weiss, M. Boehme et al., “Circulating vascular cell adhesion molecule-1 correlates with the extent of human atherosclerosis in contrast to circulating intercellular adhesion molecule-1, E-selectin, P- selectin, and thrombomodulin,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, pp. 505–512, 1997. [23] V. Braunersreuther and F. Mach, “Leukocyte recruitment in atherosclerosis: potential targets for therapeutic approaches?” Cellular and Molecular Life Sciences, vol. 63, no. 18, pp. 2079– 2088, 2006. [24] S. Pillarisetti, C. W. Alexander, and U. Saxena, “Athe- rosclerosis—new targets and therapeutics,” Current Medicinal Chemistry: Cardiovascular and Hematological Agents, vol. 2, no. 4, pp. 327–334, 2004. [25] D. H. S. Schaumann, J. Tuischer, W. Ebell, R. A. Manz, and R. Lauster, “VCAM-1-positive stromal cells from human bone marrow producing cytokines for B lineage progenitors and for plasma cells: SDF-1, ﬂt3L, and BAFF,” Molecular Immunology, vol. 44, no. 7, pp. 1606–1612, 2007. [26] W. H. Frishman, S. T. Sinatra, and M. Moizuddin, “The use of herbs for treating cardiovascular disease,” Seminars in Integrative Medicine, vol. 2, no. 1, pp. 23–35, 2004. [27] M. Xie, Z. Gu, and K. Chen, “Progress in experimental research of Radix Salviae miltiorrhizae, Fructus Crataegi and their components on atherosclerosis,” Chinese Journal of Integrative Medicine, vol. 4, pp. 311–314, 1998. [28] D. C. Ren, G. H. Du, and J. T. Zhang, “Inhibitory eﬀect of the water-soluble extract of Salvia miltiorrhiza on neutrophil- endothelial adhesion,” Japanese Journal of Pharmacology, vol. 90, no. 3, pp. 276–280, 2002. [29] Y.-H. Chen, S.-J. Lin, H.-H. Ku et al., “Salvianolic acid B attenuates VCAM-1 and ICAM-1 expression in TNF-α- treated human aortic endothelial cells,” Journal of Cellular Biochemistry, vol. 82, no. 3, pp. 512–521, 2001.